G1 THERAPEUTICS INC. - COMMON STOCK

COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

13 Jul 2022 10:15:28 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2022 17:20:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors

28 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

13 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy

02 Jun 2022 11:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jun 2022 16:45:00 By Nasdaq GlobeNewswire

G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal

20 May 2022 10:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference

18 May 2022 10:15:00 By Nasdaq GlobeNewswire

G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights

04 May 2022 06:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2022 17:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022

21 Apr 2022 08:30:01 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

06 Apr 2022 11:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2022 16:15:23 By Nasdaq GlobeNewswire

New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy

31 Mar 2022 16:05:02 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2022 17:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 Conference

01 Mar 2022 11:15:00 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

23 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022

09 Feb 2022 09:15:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2022 17:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022

04 Jan 2022 09:15:00 By Nasdaq GlobeNewswire